



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/700,101
Filing Date	11/8/2000
First Named Inventor	Glick, et al
Art Unit	1618
Examiner Name	Kim, Vickie Y
Attorney Docket Number	UM-07268

Sheet	1	of	1
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484	
	2	Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259	

Examiner Signature		Date Considered	3/30/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet 1

of 2

Attorney Docket Number

UM-07268

Complete if Known

Application Number	09/700 101
--------------------	------------

Filing Date	11/08/2000
-------------	------------

First Named Inventor	GLICK, et al
----------------------	--------------

Art Unit	1618
----------	------

Examiner Name	Kim, Vickie Y
---------------	---------------

Attorney Docket Number	UM-07268
------------------------	----------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Date Considered

3/3/24

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/700,101

Filing Date 11/08/2000

First Named Inventor Glick

Art Unit 1618

Examiner Name Kim, Vickie Y.

Attorney Docket Number UM-07268

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Parks, Daniel J. Bioorg Med Chem. Ltrs., 15,(2005), 765-770	
	4	Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861	
	5	Hulme, C. J. Org. Chem., 63,(1998), 8021-8023	
	6	Kamal, A. Synlett, 14,(2004), 2533-35	
	7	Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912	

Examiner Signature		Date Considered	3/30/06
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/700,101

Filing Date 11/08/2000

First Named Inventor Gary D. Glick et al.

Art Unit Not Assigned

Examiner Name Not Assigned

Attorney Docket Number UM-07268

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Y	1	Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56	
	2	Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183	
	3	Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132	
	4	Herranz, Medicinal Research Reviews 23 (2003) 559-603	
	5	Ramdas et al., Archives of Biochemistry and Biophysics 368 (1999) 394-400	
	6	Ursini et al., J. Med. Chem. 43 (2000) 3596-3613	

Examiner Signature

Date Considered

3/30/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-07268	Serial No.: 09/700,101
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets if Necessary)					
(37 CFR ? 1.98(b))				Applicant: Gary D. Glick <i>et al.</i> Filing Date: 11/08/2000	
				Group Art Unit:	

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	5,776,946	07/07/1998	McGeer <i>et al.</i>	514	307	08/28/1995
	2	5,288,514	2/22/940	Ellman	427	29.6	9/14/92

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
	Cite No.	Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	3	WO 99/29347	17 June 1999	WO				
	4	WO 99/58117	18 Nov 1999	WO				
	5	DE 1810423		Germany				
	6	EP 0 227 539 B1	11 Dec 1986	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	7	Walser <i>et al.</i> , J. Org. Chem. 38:3502-3507 (1973)
	8	Kim <i>et al.</i> , J. Braz. Chem. Soc. 9:375-379 (1998)
	9	Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. In Vitro - 8(5):1061-1065(1994).

Examiner:	Date Considered: 3/10/06
-----------	--------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Docket No. UM 2038.01

Appl. No. 09/700,101

INFORMATION DISCLOSURE
STATEMENT

Applicant(s)




Gary D. GLICK, et al.

Filing Date: November 8, 2000

Group Art Unit: 1614

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	08/21/01	6,277,844 B1	Spector et al.			
	2.	11/20/01	6,319,931 B1	Kroemer et al.			

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

[illegible]

EXAMINER:


DATE CONSIDERED: 3/20/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

[illegible][illegible]

RECEIVED
MAR 21 2001
TECH CENTER 1600/2900

EXAMINER: 	DATE CONSIDERED: 3/3/06
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

JAN 16 2001

Supplemental Form PTO-1489

Attorney's Docket No. 128019-203801

Application Serial No. 09/700,101

INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Gary D. GLICK, et al.

Filing Date: November 8, 2000

Group Art Unit: Unassigned

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	1.	10/01/1990	0 349 949 A2	EPO				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

[illegible]

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformity. Include a copy of this form with next communication to applicant.

154157.1

194749v1

#3

PTO/SB/08 (2/92)
Sheet 1 of 3

Form PTO-1449

Attorney's Docket No. 128019-203801

Application Serial No. 09/700,101

INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Gary D. GLICK, et al.

Filing Date: November 8, 2000

Group Art Unit: Unassigned

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	02/28/1978	4,076,823	Wade, et al.			
	2.	08/29/1978	4,110,337	Szarvasi			
	3.	01/22/1985	4,495,101	Klaubert, et al.			
	4.	06/14/1988	4,751,223	Glamkowski, et al.			
	5.	08/20/1991	5,041,438	Hsu			
	6.	06/28/1994	5,324,726	Bock, et al.			
	7.	01/28/1997	5,597,915	Chambers, et al.			
	8.	07/07/1998	5,776,946	McGeer, et al.			
	9.	01/19/1999	5,861,380	Gyorkos, et al.			
	10.	12/21/1999	6,004,942	Firestein, et al.			
	11.	06/27/2000	6,080,588	Glick			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
	12.	06/04/2000	WO 00/19200	PCT			YES	NO

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	13.	Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of <i>lpr</i> Mice," <i>Proc. Natl. Acad. Sci. USA</i> - 90:1756-1760 (1993) ✓
	14.	Adelman, N.E., et al., "Treatment of (NZB X NZW) _{F1} Disease with Anti-I-A Monoclonal Antibodies," <i>J. Exp. Med.</i> - 158:1350-1355 (1983) ✓
	15.	Baader, S.L., et al., "Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroectodermal (SK-N-LO) Cells," <i>Anticancer Research</i> - 14:221-228 (1994) ✓
	16.	Beale, P.J., et al., "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," <i>British Journal of Cancer</i> - 82(2):436-440 (2000) ✓
	17.	Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality," <i>J. Org. Chem.</i> - 62:1240-1256 (1997) ✓
	18.	Bunin, B.A., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives," <i>J. Am. Chem. Soc.</i> - 114:10997-10998 (1992) ✓
	19.	Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library," <i>Proc. Natl. Acad. Sci. USA</i> - 91:7408-4712 (1994) ✓
	20.	Chumakov, A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Binding Sites," <i>Oncogene</i> - 8:3005-3011 (1993) ✓
	21.	Cohen, P.L., et al., " <i>Lpr</i> and <i>gld</i> : Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease," <i>Annu. Rev. Immunol.</i> - 9:243-269 (1991) ✓
	22.	Crabtree, R.H., "A New Type of Hydrogen Bond," <i>Science</i> - 282:2000-2001 (1998) ✓
	23.	Desolze, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," <i>Anticancer Research</i> - 14:2291-2294 (1994) ✓

EXAMINER:

DATE CONSIDERED:

3/30/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance not considered. Include a copy of this form with next communication to applicant.

154157.1

193696v1

Form PTO-1449		Attorney's Docket No. 128019-203801	Application Serial No. 108790,101
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Gary D. GLICK, et al.	JAN 08 2001 PMT & TRADEMARK 10147
(use several sheets if necessary)		Filing Date: November 8, 2000	
OTHER DOCUMENTS (Continuation) (Including author, title, date, pertinent pages, etc.)			
24.	Doble, A., et al., "Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [³ H]PK 11195: Anatomical and Subcellular Distribution," <i>Brain Research Bulletin</i> - 18:49-61 (1987)		
25.	Donadio, J.V., et al., "Immunosuppressive Drug Therapy in Lupus Nephritis," <i>American Journal of Kidney Diseases</i> - 21(3):239-250 (1993)		
26.	Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," <i>Laboratory Investigation</i> - 61(4):447-456 (1989)		
27.	Gallant, J.E., et al., "Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine," <i>The Journal of Infectious Diseases</i> - 166:1223-1227 (1992)		
28.	Garcia-Calvo, M., et al., "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," <i>The Journal of Biological Chemistry</i> - 273(49):32608-32613 (1998)		
29.	Gorczyca, W., et al., "Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias," <i>Leukemia</i> - 7(5):659-670 (1993)		
30.	Gordon, C., et al., "Chronic Therapy with Recombinant Tumor Necrosis Factor- α in Autoimmune NZB/NZW F ₁ Mice," <i>Clinical Immunology and Immunopathology</i> - 52:421-434 (1989)		
31.	Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," <i>Journal of Medicinal Chemistry</i> - 37(10):1385-1401 (1994)		
32.	Hahn, B.H., et al., "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice," <i>Arthritis and Rheumatism</i> - 18(2):145-152 (1975)		
33.	Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MRL/l Mice," <i>J. Exp. Med.</i> - 155:1690-1701 (1982)		
34.	Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," <i>Laboratory Investigation</i> - 21(3):199-206 (1969)		
35.	Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> - 66:233-243 (1991)		
36.	Koopman, W.J., et al., "The MRL-lpr/lpr Mouse. A Model for the Study of Rheumatoid Arthritis," <i>Scand. J. Rheumatology</i> - Suppl 75:284-289 (1988)		
37.	Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," <i>Blood</i> - 80(4):879-886 (1992)		
38.	Liu, J.R., et al., "Bcl-xL is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-Induced Apoptosis," <i>Gynecologic Oncology</i> - 70:398-403 (1998)		
39.	Los, M., et al., "The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice," <i>Immunity</i> - 10:629-639 (1999)		
40.	Luria, et al., "General Virology - 3 rd edition, pp. 436-446 (1978) - Eds. John Wiley & Sons, New York		
41.	Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/lpr Mice by Administration of an Immunoglobulin-Binding peptide," <i>Nature Biotechnology</i> - 18:735-739 (2000)		
42.	McDonnell, T.J., et al., "Progression from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18)," <i>Nature</i> - 349:254-256 (1991)		
43.	Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model," <i>J. Hum. Genet.</i> - 43:2-8 (1998)		
44.	Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing lpr Gene," <i>Clin. Exp. Immunol.</i> - 63:87-94 (1986)		
45.	Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice," <i>Int. Arch. Allergy Appl. Immunol.</i> - 88:394-401 (1989)		
EXAMINER:		DATE CONSIDERED: 7/30/06	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance not considered. Include a copy of this form with next communication to applicant.			
154157.1			
193696v1			

Form PTO-1449

Attorney's Docket No. 128019-203801

Application Serial No. 09/700,101

INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Gary D. GLICK, et al.

Filing Date: November 8, 2000

Group Art Unit: Unassigned

(use several sheets if necessary)

OTHER DOCUMENTS (Continuation)

(including author, title, date, pertinent pages, etc.)

46. Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," *Seminars in Oncology* - 26(1)(Supp. 2):84-89 (1999) ✓
47. Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines," *Int. J. Cancer* - 77:913-918 (1998) ✓
48. Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," *Br. J. Cancer* - 74(3):380-386 (1996) ✓
49. Russell, J.H., et al., "Mature T Cells of Autoimmune *lpr/lpr* Mice have a Defect in Antigen-Stimulated Suicide," *Proc. Natl. Acad. Sci. USA* - 90:4409-4413 (1993) ✓
50. Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," *Clinical Immunology and Immunopathology* - 87(1):1-7 (1998) ✓
51. Sandstrom, P.A., et al., "Autocrine Production of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell Line in Serum-Free Medium," *Proc. Natl. Acad. Sci. USA* - 90:4708-4712 (1993) ✓
52. Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [³H]Ro5-4864 in Rat Brain and Kidney," *The Journal of Pharmacology and Experimental Therapeutics* - 225(1):61-69 (1983) ✓
53. Schwab, M., et al., "Amplified DNA with Limited Homology to *myc* Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and a Neuroblastoma Tumour," *Nature* - 305:245-248 (1983) ✓
54. Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/MP-lpr/lpr and MRL/MP-+/+ Mice," *The Journal of Immunology* - 132(2):633-639 (1984) ✓
55. Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," *Cell* - 67:879-888 (1991) ✓
56. Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis," *Int. J. Peptide Protein Res.* - 20:451-454 (1982) ✓
57. Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," *J. Am. Chem. Soc.* - 118:10650-10651 (1996) ✓
58. Sugimoto, T., et al., "Determination of Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and Leukemia-Lymphoma Cell Lines by a Panel of 38 Monoclonal Antibodies," *JNCI* - 73(1):51-57 (1984) ✓
59. Swanson, P.C., et al., "High Resolution Epitope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," *J. Immunology* - 152(5):2601-2612 (1994) ✓
60. Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," *J. Clin. Invest.* - 97(7):1748-1760 (1996) ✓
61. Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand," *Cell* - 76:969-976 (1994) ✓
62. Theofilopoulos, A.N., et al., "Murine Models of Systemic Lupus Erythematosus," *Advances in Immunology* - 37:269-390 (1985) ✓
63. Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," *Science* - 267:1456-1462 (1995) ✓
64. Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis," *Nature* - 356:314-317 (1992) ✓
65. White, E., "Life, Death, and the Pursuit of Apoptosis," *Genes & Development* - 10:1-15 (1996) ✓
66. Wu, G.Y., et al., "Receptor-Mediated *In Vitro* Gene Transformation by a Soluble DNA Carrier System," *The Journal of Biological Chemistry* - 262(10):4429-4432 (1987) ✓
67. Wyllie, A.H., "The Genetic Regulation of Apoptosis," *Current Opinion in Genetics & Development* - 5:97-104 (1995) ✓
68. Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," *J. Exp. Med.* - 183:1533-1544 (1996) ✓
69. Zoratti, M., et al., "The Mitochondrial Permeability Transition," *Biochimica et Biophysica Acta* - 1241:139-176 (1995) ✓

EXAMINER:

DATE CONSIDERED: 3/20/01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformity. Include a copy of this form with next communication to applicant.

154157.1

193696v1